HOME >> MEDICINE >> NEWS
US FDA grants full approval to DOXIL(R) following submission of phase III data

Bridgewater, N.J. February 7, 2005 -- The U.S. Food and Drug Administration (FDA) has granted full approval to DOXIL (doxorubicin HCl liposome injection) for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy. DOXIL, marketed in the United States by Tibotec Therapeutics, Division of Ortho Biotech Products, L.P., originally received accelerated approval for refractory ovarian cancer in June 1999. As a result of the full approval, the product label for DOXIL has been updated to include survival, time to disease progression and tumor response rate data from a randomized Phase III clinical study.

Under accelerated approval, DOXIL was indicated for the treatment of metastatic ovarian cancer in patients with disease that was refractory to both paclitaxel- and platinum-based chemotherapy regimens. This approval was based on tumor response rates from three Phase II studies. According to the terms of the accelerated approval, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) completed a randomized Phase III clinical study to formally demonstrate the drug's clinical benefit in patients with relapsed ovarian cancer. In March 2004, J&JPRD submitted a supplemental new drug application (sNDA) based on data from the Phase III study.

"The Phase III data provide evidence of the product's clinical benefit for patients with relapsed ovarian cancer," commented Alan N. Gordon, M.D., of the University of Arizona School of Medicine and Arizona Gynecologic Oncology, in Phoenix, Ariz., and lead author of the Phase III study, known as DOXIL Study 30-49.

In the randomized, multi-center, open-label, Phase III study, 474 patients with recurrent epithelial ovarian cancer were randomly assigned to receive either DOXIL 50 mg/m2 every 28 days or topotecan HCl 1.5 mg/m2/day for five consecutive days every 21 days. A total of 239 patients received DOXIL; 235 patients received
'"/>


7-Feb-2005


Page: 1 2 3

Related medicine news :

1. UNH launches 2nd spinout company with NIH grants
2. Disease testing for immigrants: Discrimination disguised as public health policy
3. Four teams awarded inaugural translational cancer research grants
4. Immigrants, beware: Living in the United States is fattening
5. Prevalence of obesity among immigrants increases with longer residency in US
6. FDA grants accelerated approval of TYSABRI, formerly antegren, for the treatment of MS
7. Dana-Farber receives CDC grants to develop health promotion/prevention programs in the work place
8. Speech recognition experts at OGI School of Science & Engineering receive nearly $700,000 in grants
9. Should compulsory screening of immigrants be part of UK public health policy?
10. NIH grants support health disparities biomedical research
11. NCCAM awards planning grants for International Centers for Research

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: FDA grants full approval DOXIL following submission phase III data

(Date:10/30/2014)... 2014 Timothy, InstaKNOT’s 4-year-old ... firefighters, showing that you are never too young to ... firefighters Tracey and Carl at the 2013 Santa Arriving ... Pompano Beach Chamber of Commerce. Tracey gave Timothy a ... Timothy wear his real fireman’s hat, and extending an ...
(Date:10/30/2014)... 2014 Don Allred Insurance, a leading ... plans for North Carolina residents, is excited to announce ... Holly Hill Mall. The new branch has been up ... customers through all facets of the insurance selection process ... spokesman Scott Allred couldn’t be happier with the timing ...
(Date:10/30/2014)... Portland, OR (PRWEB) October 30, 2014 ... law firm Hodgkinson Street LLC announces new branding ... Hodgkinson Street Mepham . After David Mepham’s promotion ... revitalizes their brand and website to include Mepham’s name ... leading medical malpractice and mediation firm, the decision to ...
(Date:10/30/2014)... 2014 Paramount Rx, a full-service prescription ... efforts to help people save money through its innovative ... for prescription drugs in the new health care system, ... to bridge the relationship between consumers, businesses and the ... challenges people face today with medical costs is the ...
(Date:10/30/2014)... HealthDay Reporter , WEDNESDAY, Oct. ... with prostate cancer who also have certain heart problems may ... new study suggests. , , The therapy in question is called ... reduce levels of male hormones to prevent the growth of ... research, this hormone therapy was linked to triple the risk ...
Breaking Medicine News(10 mins):Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 3Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 4Health News:Allred Insurance Satellite Office Grand Opening 2Health News:Hodgkinson Street Mepham Rebrands 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3
(Date:10/30/2014)... FRANCISCO , Oct. 30, 2014  Nektar Therapeutics ... results for the third quarter ended September 30, 2014 ... U.S.-based financial markets. Howard Robin , president and ... review the results beginning at 5:00 p.m. Eastern Time ... press release and a live audio-only Webcast of the ...
(Date:10/30/2014)... , Oct. 30, 2014  CytRx Corporation ... and development company specializing in oncology, today announced ... its lead drug candidate, aldoxorubicin.  The presentation, titled, ... Approach," will be given by Sant P. ... Oncology Center and principal investigator of the Company,s ...
(Date:10/30/2014)... -- , Extensively hydrolyzed milk formula with LGG ... Cow milk protein allergy (CMPA) is the leading cause of food ... has been managed by eliminating milk proteins from a ... is possible to help build of oral tolerance to ... the first year of life by using an extensively ...
Breaking Medicine Technology:Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4Experts Present Latest Research at Allergy Day 2Experts Present Latest Research at Allergy Day 3
Cached News: